Literature DB >> 16629535

Early experience of sexual intercourse--a risk factor for cervical cancer requiring specific intervention for teenagers.

Manop Kanato1, Kesinee Saranrittichai.   

Abstract

There is consensus that the main risk factor for cervical cancer development is persistent infection with high-risk group human papilloma viruses (HPVs), together with smoking, and reproductive history. Since sexual behaviour determines exposure to HPVs and the adolescent period may be particularly important in this regard it is of interest to consider behavioural determinants of teenagers. In one survey conducted in Khon Kaen, Thailand, some 62% percent of male and 19.3 % of female respondents aged 13-15 years reported having experienced sexual desire, and 19.1% of male and 4.7 % of female respondents admitted to sexual intercourse. The possibility that this might impact on HPV infection rates, with added risk due to the physical trauma associated with pregnancy and illegal abortions, indicates that more attention needs to education of early teens, not only for avoidance of HIV and AIDS, but also for prevention of cervical cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16629535

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  Prevalence and social correlates of sexual intercourse among school-going adolescents in Thailand.

Authors:  Karl Peltzer; Supa Pengpid
Journal:  ScientificWorldJournal       Date:  2011-10-20

2.  Cervical cancer risk factors and feasibility of visual inspection with acetic acid screening in Sudan.

Authors:  Ahmed Ibrahim; Vibeke Rasch; Eero Pukkala; Arja R Aro
Journal:  Int J Womens Health       Date:  2011-04-04

3.  Improving Sexual Health Education Programs for Adolescent Students through Game-Based Learning and Gamification.

Authors:  Hussein Haruna; Xiao Hu; Samuel Kai Wah Chu; Robin R Mellecker; Goodluck Gabriel; Patrick Siril Ndekao
Journal:  Int J Environ Res Public Health       Date:  2018-09-17       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.